Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Enterprise Value : HK$6,158 Mil (As of Mar. 29, 2025)

Biocytogen Pharmaceuticals (Beijing) Co Enterprise Value Chart

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Enterprise Value	Get a 7-Day Free Trial				10,030.78	8,293.25	4,905.04	3,219.56	3,531.64

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's Enterprise Value

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocytogen Pharmaceuticals (Beijing) Co's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Enterprise Value falls into.

Biocytogen Pharmaceuticals (Beijing) Co Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Biocytogen Pharmaceuticals (Beijing) Co's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as

Biocytogen Pharmaceuticals (Beijing) Co's Enterprise Value for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co  (HKSE:02315) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Biocytogen Pharmaceuticals (Beijing) Co's EV-to-EBIT for today is

Biocytogen Pharmaceuticals (Beijing) Co's current Enterprise Value is HK$6,158 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was HK$144 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Biocytogen Pharmaceuticals (Beijing) Co's EV-to-EBITDA for today is:

Biocytogen Pharmaceuticals (Beijing) Co's current Enterprise Value is HK$6,158 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was HK$144 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Biocytogen Pharmaceuticals (Beijing) Co's EV-to-Revenue for today is:

Biocytogen Pharmaceuticals (Beijing) Co's current Enterprise Value is HK$6,158 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was HK$1,050 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Biocytogen Pharmaceuticals (Beijing) Co's EV-to-FCF for today is:

Biocytogen Pharmaceuticals (Beijing) Co's current Enterprise Value is HK$6,158 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was HK$202 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co Enterprise Value Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description